Chemistry:SAGE-324
From HandWiki
SAGE-324, also known as BIIB124, is an experimental drug. It is a neurosteroid that works as a GABAA receptor positive allosteric modulator.[1][2][3]
SAGE-324 was being developed by Biogen for the treatment of essential tremor.[4] Its development was discontinued in 2024 due to lack of efficacy in Phase 2 clinical trials.[5]
References
- ↑ Cerne, Rok; Lippa, Arnold; Poe, Michael M.; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Golani, Lalit K.; Cook, James M. et al. (June 2022). "GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors". Pharmacology & Therapeutics 234. doi:10.1016/j.pharmthera.2021.108035.
- ↑ Witkin, Jeffrey M.; Lippa, Arnold; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Biggerstaff, Andrew; Kivell, Bronwyn M.; Knutson, Daniel E. et al. (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology Biochemistry and Behavior 213. doi:10.1016/j.pbb.2021.173321. PMID 35041859.
- ↑ Quagliato, Laiana A.; Carta, Mauro G.; Nardi, Antonio E. (September 2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID 36099401.
- ↑ Ondo, William (1 January 2022). "Chapter Eleven - Enhancing GABA inhibition is the next generation of medications for essential tremor". International Review of Neurobiology. 163. Academic Press. pp. 317–334. doi:10.1016/bs.irn.2022.02.007. ISBN 978-0-323-89974-1. https://www.sciencedirect.com/science/article/abs/pii/S0074774222000083.
- ↑ "Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor". Biogen (Press release). 2024-07-24. Retrieved 2024-07-24.
 |  |
